IBI376 in Patients With Relapsed or Refractory Follicular Lymphoma/Marginal Zone Lymphoma

PHASE2CompletedINTERVENTIONAL
Enrollment

81

Participants

Timeline

Start Date

April 7, 2020

Primary Completion Date

July 27, 2021

Study Completion Date

November 21, 2023

Conditions
Indolent Non-hodgkin Lymphoma
Interventions
DRUG

IBI376

IBI376 20 mg po. once daily for 8 weeks ,followed by 2.5mg once daily

Trial Locations (1)

Unknown

Ruijin hospital, school of medicine, Shanghai jiao tong university, Shanghai

All Listed Sponsors
lead

Innovent Biologics (Suzhou) Co. Ltd.

INDUSTRY